DiPalma J A
Division of Gastroenterology, University of South Alabama College of Medicine, Mobile 36693, USA.
J Clin Gastroenterol. 2001 Jan;32(1):19-26. doi: 10.1097/00004836-200101000-00006.
Gastroesophageal reflux disease (GERD) affects more than one third of the population. It is generally a chronic condition and has the potential to be serious. Some patients with GERD experience persistent daytime or nighttime heartburn and some sustain severe damage, including ulceration, stricture, and Barrett's esophagus, which can predispose to development of adenocarcinoma. Extraesophageal manifestations of GERD can include otolaryngologic, respiratory, and cardiac problems. Severe GERD responds best to agents that suppress gastric acid secretion. Of these, proton pump inhibitors (PPIs) provide the most effective control of gastric acidity and are, therefore, the medical treatment of choice. In fact, nonresponse to a PPI should raise the suspicion that the diagnosis is not GERD. Proton pump inhibitors are quickly becoming the treatment of choice for GERD, especially for severe or refractory cases. For patients whose GERD is refractory even to PPIs or who are unwilling to face years of PPI therapy, antireflux surgery remains an option.
胃食管反流病(GERD)影响着超过三分之一的人口。它通常是一种慢性疾病,有可能很严重。一些GERD患者会经历持续的白天或夜间烧心,一些患者会遭受严重损害,包括溃疡、狭窄和巴雷特食管,这些情况可能会增加腺癌发生的风险。GERD的食管外表现可包括耳鼻喉科、呼吸道和心脏问题。严重的GERD对抑制胃酸分泌的药物反应最佳。其中,质子泵抑制剂(PPI)能最有效地控制胃酸度,因此是首选的药物治疗方法。事实上,对PPI无反应应引起对诊断不是GERD的怀疑。质子泵抑制剂正迅速成为GERD的首选治疗方法,尤其是对于严重或难治性病例。对于那些GERD即使对PPI也难治或不愿接受多年PPI治疗的患者,抗反流手术仍是一种选择。